Mattia Galli/LinkedIn
Sep 11, 2025, 08:32
Rivaroxaban vs Apixaban in AFib and PAD – What the Data Say
Mattia Galli, Assistant Professor at Sapienza Università di Roma, Associate Editor of European Heart Journal, shared a post on X:
”Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.”
Read more here.


Stay updated with Hemostasis Today.
-
Nov 21, 2026, 08:36Sangwan Sim: ASH 2026 to Highlight Research into PU.1-Related Neutrophil Dysfunction
-
Nov 21, 2026, 08:29Liz Tate: First Percutaneous LAAO Procedure Performed at The Park Hospital for Stroke Prevention
-
Nov 21, 2026, 08:26Robert Sidonio: WFH Webinar to Address Key Challenges in Rare Bleeding Disorders Care
-
Nov 21, 2026, 08:21Jenni Majumdar: What Changing Blood Transfusion Guidelines Mean for Patients and Surgical Teams
-
Nov 21, 2026, 08:17Doaa El Demerdash: The Bridge Meeting Fosters International Dialogue on Hemophilia Care
-
Nov 21, 2026, 08:16Emily Branchard: Uncoupling Anticancer and Antiplatelet Effects of Dipyridamole Analogs
-
Nov 21, 2026, 08:10Rory R Koenen: Xin Xin Earns PhD for Research on Extracellular Vesicles and Vascular Inflammation
-
Nov 21, 2026, 08:06Andrew Hill: How Do You Build Loyalty when Financial Incentives Are off the Table?
-
Nov 21, 2026, 08:00Kevin Dean: How Leptin Receptor Positive Stromal Cells Regulate Platelet Production